Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315221000456/form10-k.htm
SEC Filings
ANIX Annual Reports
ANIX Quarterly Reports
10-Q Quarterly Report June 2022
10-Q Quarterly Report March 2022
10-Q Quarterly Report September 2021
10-Q Quarterly Report June 2021
10-Q Quarterly Report March 2021
10-Q Quarterly Report September 2020
10-Q Quarterly Report June 2020
10-Q Quarterly Report September 2019
10-Q Quarterly Report June 2019
10-Q Quarterly Report March 2019
10-Q Quarterly Report June 2022
10-Q Quarterly Report March 2022
10-Q Quarterly Report September 2021
10-Q Quarterly Report June 2021
10-Q Quarterly Report March 2021
10-Q Quarterly Report September 2020
10-Q Quarterly Report June 2020
10-Q Quarterly Report September 2019
10-Q Quarterly Report June 2019
10-Q Quarterly Report March 2019
ANIX Corporate News
Event for Officers April 2022
Financial Exhibit
Regulated Disclosure
Vote of Security Holders March 2022
Shareholder Nomination December 2021
Regulated Disclosure October 2021
Other Events October 2021
Ending Agreement June 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders May 2021
Bylaw Change
Event for Officers
Financial Exhibit April 2021
Financial Exhibit
New Agreement March 2021
New Agreement January 2021
Event for Officers
April 2022
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
March 2022
Shareholder Nomination
December 2021
Regulated Disclosure
October 2021
Other Events
October 2021
Ending Agreement
June 2021
Financial Exhibit
Regulated Disclosure
Vote of Security Holders
Regulated Disclosure
Vote of Security Holders
May 2021
Bylaw Change
Event for Officers
Financial Exhibit
Event for Officers
Financial Exhibit
April 2021
Financial Exhibit
New Agreement
New Agreement
March 2021
New Agreement
January 2021
Last10K.com | 10-K Annual Report Thu Jan 07 2021
Document and Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Oct. 31, 2020 | Jan. 07, 2021 | Apr. 30, 2020 | |
| Cover [Abstract] | |||
| Entity Registrant Name | Anixa Biosciences Inc | ||
| Entity Central Index Key | 0000715446 | ||
| Document Type | 10-K | ||
| Document Period End Date | Oct. 31, 2020 | ||
| Amendment Flag | false | ||
| Current Fiscal Year End Date | --10-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business Flag | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 35,235,950 | ||
| Entity Common Stock, Shares Outstanding | 26,076,819 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2020 |
View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
Tools
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Other - Other Highlight
35 The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $98,000 to approximately $74,000 in fiscal year 2020, from approximately $172,000 in fiscal year 2019, as Certainty's net loss decreased.
-
Revenue - Product Highlight
Accordingly, the performance obligations from the license were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
-
Revenue - Product Highlight
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
-
Revenue - Product Highlight
Cash provided by financing activities was approximately $9,407,000, resulting from the sale of 3,854,305 shares of common stock in at-the-market equity offerings of approximately $9,266,000, the proceeds from exercise of stock options of approximately $122,000 and the proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $18,000.
-
Financial - Expense Highlight
Research and development expenses are related to the development of our cancer diagnostics and therapeutics programs and our anti-viral drug program, and decreased by approximately $1,092,000 to approximately $4,381,000 in fiscal year 2020, from approximately $5,473,000 in fiscal year 2019.
-
Financial - Expense
The decrease in Certainty's net...Read more
-
Financial - Income
Interest income decreased to approximately...Read more
-
Financial - Cash Flow
We can give no assurance...Read more
-
Financial - Cash Flow
The impairment recorded in fiscal...Read more
-
Other - Other
As a result, our cash,...Read more
-
Financial - Expense
General and administrative expenses decreased...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Equity
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Details)
Business And Funding
Business And Funding (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Impact Of Coronavirus Pandemic
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Income Tax Provision (Benefit) (Details)
Income Taxes - Schedule Of Reconciliation Of Income Taxes (Details)
Leases
Leases (Details Narrative)
Leases (Tables)
Leases - Schedule Of Minimum Lease Payments (Details)
Leases - Schedule Of Operating Lease (Details)
Segment Information
Segment Information (Details Narrative)
Segment Information (Tables)
Segment Information - Schedule Of Segment Information (Details)
Shareholders' Equity
Shareholders' Equity (Details Narrative)
Shareholders' Equity (Tables)
Shareholders' Equity - Schedule Of Option Activity (Details)
Shareholders' Equity - Schedule Of Outstanding And Exercisable (Details)
Shareholders' Equity - Schedule Of Warrants Activity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Changes In Noncontrolling Interest (Details)
Summary Of Significant Accounting Policies - Schedule Of Hierarchy Of Financial Assets (Details)
Summary Of Significant Accounting Policies - Schedule Of Weighted Average Assumptions Used In Estimating Fair Value Of Stock Options (Details)
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Exhibit 4.2: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.10: Material Contract
Exhibit 10.13: Material Contract
Exhibit 10.14: Material Contract
Exhibit 14: Code Of Ethics
Exhibit 21: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-21-000456
Submitted to the SEC: Thu Jan 07 2021 4:15:57 PM EST
Accepted by the SEC: Thu Jan 07 2021
Period: Saturday, October 31, 2020
Industry: Medical Laboratories
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/anix/0001493152-21-000456.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...